COMMUNIQUÉS West-GlobeNewswire

Powerful Oral Steroids for Cutting Cycles 2026: Crazy Bulk Launches Effective Cutting Steroid Stacks for Strength and Muscle Growth
23/05/2026
Discover CrazyBulk’s popular steroid alternatives formulated for muscle growth, strength development, cutting phases, and bodybuilding performance support in 2026. New York City, NY, May 23, 2026 (GLOBE NEWSWIRE) -- [...]
Heallexa Launches AI Powered Healthcare Directory With Over 6 Million Provider Profiles to Make Finding and Booking Care More Convenient
23/05/2026
Patients can find care faster through Heallexa, while early bird providers can claim lifetime access and increase visibility without paying per appointment fees. Dallas, Texas, May 23, 2026 (GLOBE NEWSWIRE) -- Heallexa [...]
Dempster Therapeutic Services Launches “Chicago Speech Therapy” And “Polski logopeda” Digital Storefronts With Instant Online Booking, Patient Portal, And Rapid Access To Award-Winning Speech Therapy Services
23/05/2026
New Custom Digital Storefronts Allow Chicago-Area Families To Secure Speech Therapy Appointments In English Or Polish In Less Than 10 Days Chicago, IL, May 23, 2026 (GLOBE NEWSWIRE) -- Dempster Therapeutic Services [...]
Roota Hair Growth Roll-On Scalp Serum & Roota Hair Activator Spray Under Investigation: Evaluating the Clinically-Tested Hair Care Formula's Claims
23/05/2026
How Roota's Plant-Based Rosemary, Biotin, Caffeine, Redensyl, and AnaGain Roll-On Serum Is Designed for Hair Thinning, Shedding, and Scalp Care in 2026 Aurora, CO, May 22, 2026 (GLOBE NEWSWIRE) -- These statements have [...]
Organifi Parasite Cleanse Kit: The Most Effective Herbal Parasite Binding Detox Supplements on the Market
23/05/2026
Organifi Parasite Cleanse Capsules and Bind and Restore Tincture Ingredients, Mimosa Seed and Fulvic Acid Dosages, and 7-Day Herbal Cleanse Routine Explained San Diego, CA, May 22, 2026 (GLOBE NEWSWIRE) -- These [...]
Slim Tide Under Investigation: Critical Research Details Ingredients' Effectiveness for Metabolic & Digestive Support
23/05/2026
Slim Tide Consumer Research, Legitimacy Verification, Side Effects, Cost, Refund Policy, and Akkermansia Probiotic Capsule Ingredients for Gut Health Explained Largo, FL, May 22, 2026 (GLOBE NEWSWIRE) -- These [...]
Calidi Biotherapeutics Provides Required NYSE American Disclosure
23/05/2026
SAN DIEGO, May 22, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or “the Company”), a biotechnology company pioneering the development of targeted genetic medicines, today advised [...]
GlycoPulse Claims Evaluated: Most Advanced Blood Sugar Support Ingredients for Healthy Glucose Management by Glyco Pulse
22/05/2026
GlycoPulse Ingredient Breakdown: Chromium Picolinate, Berberine HCL, Gymnema, Cinnamon, and Bitter Melon Blood Sugar Support Capsule with 180-Day Guarantee Largo, FL, May 22, 2026 (GLOBE NEWSWIRE) -- These statements [...]
Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock
22/05/2026
– Financing includes leading U.S. biotechnology institutional investors and mutual funds – LOS ANGELES, CA, May 22, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a [...]
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
22/05/2026
SAN CARLOS, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal [...]
Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing
22/05/2026
STAFFORD, Texas, May 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) ("Greenwich" or the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO- [...]
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
22/05/2026
NOVATO, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare [...]
NANOBIOTIX Announces Full Exercise of Underwriters’ Over-Allotment Option, Bringing Gross Proceeds of Offering to Approximately $100 Million
22/05/2026
PARIS and CAMBRIDGE, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “ Nanobiotix ” or the “ Company ”), a late-clinical stage biotechnology company pioneering physics-based [...]
NANOBIOTIX annonce l’exercice integral de l’option de surallocation, portant le produit de l'offre a 100 millions de dollars
22/05/2026
PARIS et CAMBRIDGE, Mass., 22 mai 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – « Nanobiotix » ou la « Société »), une société de biotechnologie au stade clinique et en phase avancée qui développe [...]
SCYNEXIS Announces One-for-Eight Reverse Stock Split
22/05/2026
SCYNEXIS’s Common Stock to Begin Trading on Post-Split Adjusted Basis on June 1, 2026 JERSEY CITY, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS”), a clinical-stage biotechnology [...]
XTL Announces Receipt of Staff Delist Determination from Nasdaq
22/05/2026
RAMAT GAN, ISRAEL, May 22, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced today that it has received a letter (the “Letter”) from The Listing [...]
Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis
22/05/2026
Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative [...]
Abivax présente ses résultats financiers du T1 2026 et les données à trois ans de l’étude 108, un essai d’extension ouvert de phase 2a/2b évaluant l’obéfazimod après réduction de dose dans la RCH
22/05/2026
Abivax présente ses résultats financiers du T1 2026 et les données à trois ans de l’étude 108, un essai d’extension ouvert de phase 2a/2b évaluant l’obéfazimod après réduction de dose dans la RCH L’analyse intermédiaire [...]
Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026
22/05/2026
SAN DIEGO, May 22, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in the Jefferies Global Healthcare Conference, taking place June 2-4, [...]

Pages